164 related articles for article (PubMed ID: 7540039)
1. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Sleijfer DT; Kaye SB; de Mulder PH; ten Bokkel Huinink WW; Spaander PJ; de Pauw M; Sylvester R
Br J Cancer; 1995 Jun; 71(6):1311-4. PubMed ID: 7540039
[TBL] [Abstract][Full Text] [Related]
2. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
de Wit R; Stoter G; Sleijfer DT; Neijt JP; ten Bokkel Huinink WW; de Prijck L; Collette L; Sylvester R
Br J Cancer; 1998 Sep; 78(6):828-32. PubMed ID: 9743309
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
6. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
7. [BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors].
Mori Y; Shima H; Ihara H; Yabumoto H; Iwasaki A; Yoshioka M; Ikoma F
Hinyokika Kiyo; 1992 Oct; 38(10):1139-42. PubMed ID: 1282774
[TBL] [Abstract][Full Text] [Related]
8. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
9. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
10. Potential advances in combination chemotherapy for advanced testicular cancer.
Kaye SB; Stoter G; Sleijfer D; Jones W; Ten Bokkel Huinink W; Splinter T; Van Oosterom A; Harris A; Boven E; De Pauw M
Prog Clin Biol Res; 1988; 269():461-9. PubMed ID: 2455913
[TBL] [Abstract][Full Text] [Related]
11. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastatic seminoma by chemotherapy.: an experience].
Komatsubara S; Itoi T; Watanabe M; Kitamura Y; Koike T
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):666-72. PubMed ID: 11109817
[TBL] [Abstract][Full Text] [Related]
13. [Advanced germinal tumors of the testicle: clinical experience with cisplatin, bleomycin and vinblastine (PVB) or etoposide (BEP)].
Alonso Curbera G; González-Manzano R; Aramendía Beitia JM; Martínez Monge R; Agüera Fernández L; Rebollo Liceaga J
Rev Med Univ Navarra; 1993; 38(1):13-8. PubMed ID: 8711305
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
16. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
Kawai K; Hinotsu S; Tomobe M; Akaza H
Jpn J Clin Oncol; 1998 Sep; 28(9):546-50. PubMed ID: 9793027
[TBL] [Abstract][Full Text] [Related]
17. Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma.
Gietema JA; Willemse PH; Mulder NH; Oldhoff J; de Vries EG; Sleijfer DT
Eur J Cancer; 1991; 27(11):1376-9. PubMed ID: 1720634
[TBL] [Abstract][Full Text] [Related]
18. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
19. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
